



### **Therapeutic Interchange for Anti-Glaucoma Agents/ Prostaglandins**

Patients under the age of 18 years old are excluded from this interchange.

Ordered As	Substitute To
Brinzolamide 1% (Azopt)	Dorzolamide 2% (Trusopt) 1 gtt affected eye(s) TID
Brimonidine 0.1% or 0.15% (Alphagan P)	Brimonidine 0.2% (Alphagan)
Bimatoprost 0.01% (Lumigan)	Latanoprost 0.005% (Xalatan) 1 gtt affected eye(s) once daily in the evening
Tafluprost 0.0015% (Zioptan)	
Travoprost 0.004% (Travatan Z)	
Dorzolamide 2% and timolol 0.5% (Cosopt)	Dorzolamide 2% (Trusopt) 1 gtt affected eye(s) BID + Timolol 0.5% (Timoptic) 1 gtt affected eye(s) BID
Brimonidine 0.2% and timolol 0.5% (Combigan)	Brimonidine 0.2% (Alphagan) 1 gtt affected eye(s) BID + Timolol 0.5% (Timoptic) 1 gtt affected eye(s) BID
Latanoprost 0.005% and timolol 0.5% (Xalacom)	Latanoprost 0.005% (Xalatan) 1 gtt affected eye(s) once daily in the evening + Timolol 0.5% (Timoptic) 1 gtt affected eye(s) BID
Brinzolamide 1% and brimonidine 0.2% (Simbrinza)	Dorzolamide 2% (Trusopt) 1 gtt affected eye(s) BID + Brimonidine 0.2% (Alphagan) 1 gtt affected eye(s) BID

***Clinical judgment is required when switching patients with preservative allergies or on interacting drugs***

Reference:

1. Xalatan package insert. Woodstock, IL: Pfizer: 2018 March
2. Lumigan package insert. Irvine, CA: Allergan: 2018 March
3. Travatan Z package insert. Fort Worth, TX: Alcon Laboratories: 2018 March
4. DRUGDEX System [Internet database]. Greenwood Village, CO: Thomson Health Care. Updated periodically
5. Yilmaz, Suzan Guven, et al. "The efficacy and safety of bimatoprost/Timolol maleate, latanoprost/Timolol maleate, and travoprost/Timolol maleate fixed combinations on 24-h IOP." *International Ophthalmology*, 2017, doi:10.1007/s10792-017-0601-8.
6. Mishra, Deepak, Bibhuti Prassan Sinha, and Mahendra Singh Kumar. "Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma." *Korean Journal of Ophthalmology : KJO* 28.5 (2014): 399–407. PMC. Web. 14 Mar. 2018.